Shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP) have been assigned a consensus recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $24.60.
Several research analysts have commented on GEMP shares. Zacks Investment Research lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. HC Wainwright started coverage on shares of Gemphire Therapeutics in a research note on Thursday, August 31st. They set a “buy” rating and a $21.00 price objective for the company. Canaccord Genuity reaffirmed a “buy” rating and set a $31.00 price objective on shares of Gemphire Therapeutics in a research note on Monday, October 23rd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $22.00 price objective on shares of Gemphire Therapeutics in a research note on Friday, October 27th. Finally, Roth Capital started coverage on shares of Gemphire Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective for the company.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Week Herald and is the property of of Week Herald. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://weekherald.com/2017/12/04/gemphire-therapeutics-inc-gemp-receives-24-40-average-target-price-from-analysts.html.
Gemphire Therapeutics (GEMP) traded up $0.14 during midday trading on Monday, reaching $9.50. 14,375 shares of the company’s stock traded hands, compared to its average volume of 37,601. Gemphire Therapeutics has a 52 week low of $7.20 and a 52 week high of $21.59.
Several institutional investors and hedge funds have recently modified their holdings of GEMP. Renaissance Technologies LLC purchased a new stake in shares of Gemphire Therapeutics during the first quarter valued at $184,000. Northpointe Capital LLC purchased a new stake in shares of Gemphire Therapeutics during the second quarter valued at $3,472,000. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Gemphire Therapeutics by 1.7% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock valued at $1,959,000 after purchasing an additional 2,500 shares during the period. Vanguard Group Inc. boosted its stake in shares of Gemphire Therapeutics by 137.6% during the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after purchasing an additional 17,892 shares during the period. Finally, GM Advisory Group Inc. purchased a new stake in shares of Gemphire Therapeutics during the second quarter valued at $457,000. 32.91% of the stock is owned by hedge funds and other institutional investors.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.